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FINE GRANULAR DEPOSITION OF CLONAL IMMUNOREACTIVITY ON
PODOCYTE CELL BODIES: A PRIMARY PODOCYTOPATHYMARKER
AND POTENTIAL CLUE TO DISEASE MECHANISM
JUNBO CHEN
ABSTRACT
Minimal change disease (MCD) and primary (idiopathic) focal segmental
glomerulosclerosis (1FSGS), referred to collectively as “primary podocytopathies”, are
major causes of nephrotic syndrome in children and adults, and are thought to be due to
direct podocyte damage visible only at the electron microscopic level. Lupus
podocytopathy (LP) is a newly recognized entity that involves severe podocyte injury in
the setting of systemic lupus erythematosus, in the complete absence of peripheral
capillary wall immune deposits. All of these pathologic diagnoses hinge on the
ultrastructural finding of severe podocyte injury and foot process effacement. In
addition to these ultrastructural changes, we have observed the presence of fine granular
anti-IgG antibody immunoreactivity on podocyte cell bodies in kidney biopsies of
patients with MCD, LP, and some patients with the tip lesion variant and NOS variants of
1FSGS. To validate this finding, we compared antibody staining from primary
podocytopathy biopsies with those in biopsies from patients with other disease states,
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including lesions associated with severe podocyte injury in the absence of immune
deposits: secondary (adaptive) focal segmental glomerulosclerosis, thin basement
membrane disease, diabetic nephropathy, and renal amyloidosis. We found that a fine
granular pattern of anti-IgG immunoreactivity on podocyte cell bodies is a specific
morphologic feature of the primary podocytopathies, including virtually all cases of
MCD that we encountered, some instances of tip lesion variant and NOS variant of
1FSGS, and one cases of LP. The antigen targeted by the anti-IgG immunostaining in
these biopsies exhibited one of several oligoclonal IgG heavy chain subtype plus light
chain profiles. Ultra-high resolution microscopy revealed fine linear anti-IgG staining
along filtration slit diaphragms, suggesting that IgG deposition may potentially be
targeting a filtration slit-associated antigen such as podocin. Our findings suggest the
possibility of a direct antibody-mediated mechanism of podocyte injury in the primary
podocytopathies, one that potentially targets podocyte-specific protein structures, and
which may provide a specific and more rapid diagnostic marker for this group of diseases.
The findings also suggest an etiologic relationship between MCD and some instances of
1FSGS.
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1INTRODUCTION
Structure of the Glomerulus
The glomerulus, a small cluster of intertwined capillaries about 200 micrometers
in diameter, is the individual filtration unit of the kidney. Each human kidney contains
about 1,000,000 glomeruli. The structure of a glomerulus is shown at the ultrastructural
level in Figure 1. The glomerulus is surrounded by Bowman’s capsule, a thick basement
membrane structure which is lined with parietal epithelial cells. Glomerular capillaries
contain three compartments - fenestrated endothelial cells, glomerular basement
membrane with type IV collagen chains and heparan sulfate, and visceral epithelial cells
(also called “podocytes”) which project foot-like processes that attach the cell to the
basement membrane. Adjacent processes from neighboring cells are connected by a thin
zipper-like-pattern membrane, called the slit diaphragm (SD) (Figure 2). These three
components compose the glomerular filtration barrier, which is responsible for filtration
of blood plasma. Molecules are filtered according to size and charge selectivity.
Mesangial cells are another component of the glomerulus that supports the glomerular
capillaries. Mesangial cells can also release inflammation mediators that they usually
produce in glomerular disease.[1]
Two actin-associated proteins of the podocyte cytoskeleton, α-actinin-4 and
synaptopodin, are necessary to maintain podocyte adhesion and shape, particularly the
shape of the podocyte foot processes (FP).[3] Actin polymerization is a dynamic and
2tightly regulated process that provides podocytes with mechanical support to modulate
FP shape and orchestrate cell motility and migration.[3] Synaptopodin is a proline-rich
actin-associated protein expressed in neurons and differentiated podocyte FPs.
Synaptopodin binds to podocin, providing mechanical support, and to α-actinin-4,
regulating its bundling activity.[3-6] Phosphorylation of synaptopodin protects it from
cathepsin-L-mediated degradation and helps maintain integrity of the FP.[4-6] Podocin is
an intracellular lipid-raft associated component of the glomerular foot-process
membrane, and is located at the insertion of the slit-diaphragm into the secondary foot
process[7-9]. Podocin is a member of the stomatin family of proteins, and is expressed in
podocytes of both the fetal and mature kidney. Nephrin is a specialized,
podocyte-specific junctional protein, and a critical structural component of the slit
diaphragm. Oligomerization of podocin induces nephrin to cluster and form the slit
diaphragm assembly, where another protein, CD2AP serves as an adapter to the overall
actin network[8,10]. The presence of intact podocin is needed for nephrin transport to the
cell membrane, as well as for podocyte intracellular signaling[11]. The inter-relationship
of these proteins in the foot processes and slit diaphragm complex is shown schematically
in Figure 3. Based upon the functional role of the slit diaphragm, it seems logical that
alterations in proteins associated with the slit-diaphragm complex lead to proteinuria.
This has been shown to occur in both experimental models[12-16] and in human diseases[17].
3Figure 1. Low-power electron micrograph of renal glomerulus. CL, capillary lumen;
EP, visceral epithelial cells with foot processes; END, endothelium; MES, mesangium.
4Figure 2. Glomerular filter consisting, from bottom to top, of fenestrated
endothelium, basement membrane, and foot processes of epithelial cells. Note the
filtration slits (red arrows) and diaphragm situated between the foot processes. Also
note a foot process that is shared between adjacent capillary loops (red arrowhead). Bar
= 500 nm.
Figure 3. Molecular anatomy of the glomerular filtration barrier in the healthy
state. FP : foot processes, GBM : glomerular basement membrane, EC : endothelial cells,
FA : focal adhesome
Nephrotic Syndrome
Nephrotic syndrome is a clinical syndrome resulting from loss of glomerular
barrier function secondary to podocyte injury. The key manifestations of the nephrotic
5syndrome include: 1) Massive proteinuria, with the daily loss of 3.5 gm or more of
protein (less in children); 2) Hypoalbuminemia, with plasma albumin levels less than 3
gm/dL; 3) Generalized edema; 4) Hyperlipidemia and lipiduria. The causes of nephrotic
syndrome are classified into primary and secondary nephrotic types of glomerular disease.
In children in North America, the nephrotic syndrome is almost always caused by a
primary lesion to the kidney; but in adults, it may be associated with a systemic disease.
The most frequent systemic causes of the nephrotic syndrome are diabetes, amyloidosis,
and systemic lupus erythematosus (SLE). The most common primary glomerular lesions
are minimal-change disease, membranous glomerulopathy, and focal segmental
glomerulosclerosis.[2]
Minimal Change Disease
Minimal change disease (MCD) is the most common cause of the nephrotic
syndrome (NS) in children, with a peak incidence is between 2 and 6 years of age.
MCD also accounts for 10 to 15% of cases of primary nephrotic syndrome in adults.[25] It
is characterized by a uniform and diffuse effacement or loss of podocyte foot processes,
these being replaced by a rim of cytoplasm. In addition, podocytes often show other signs
of injury including vacuolization, swelling and formation of microvilli, by electron
microscopy (Figure 4B). Despite these ultrastructural changes, the glomeruli appear
virtually normal by light microscopy (Figure 4A). The proteinuria usually is highly
selective, most of the protein being albumin. Most children (>90%) with MCD respond
6rapidly to corticosteroid therapy. Although adults are slower to respond, their long-term
prognosis is also excellent.
To date, definitive diagnosis of this disease entity requires ultrastructural
examination of biopsy tissue, which is a time consuming and labor-intensive process
whose results are only available several days after light microscopic examination has
been completed. In children presenting with NS, renal biopsy is not usually necessary,
given the high likelihood of NS being caused by MCD in this population (~70-90% in
those over one year of age)[26]. However, given the wide differential diagnosis of NS in
adults, renal biopsy and ultrastructural examination are currently required in this patient
population. Patients are usually treated presumptively with steroids while a diagnosis is
awaited.
Another complicating factor in the diagnosis of MCD in the adult population is
that severe podocyte injury and foot process effacement are not specific findings, in that
they are also present in other proteinuric states (e.g., various forms of FSGS,
membranous glomerulopathy, diabetic nephropathy). Thus, even EM findings cannot
entirely rule out other lesions that are associated with diffuse foot process effacement,
such as primary focal segmental glomerulosclerosis (FSGS). It is only when effacement
is associated with normal glomeruli by light microscopy that the diagnosis of
minimal-change disease can be made, but it nevertheless remains uncertain since biopsies
may miss focal glomerular lesions that would indicate a different diagnosis. A more rapid
and specific approach to the diagnosis of MCD would potentially allow for earlier
initiation and optimization of treatment.
7MCD, along with 1FSGS, represents a spectrum of pathology caused by a specific
insult to the podocyte, here termed the ‘primary podocytopathies’[27]. In addition, a
recently described entity known as lupus podocytopathy (LP), while referred to as a
‘secondary podocytopathy’ due to it’s association with systemic disease (SLE), may also
involve an injury mechanism that targets the podocyte[24]. The etiology of these
podocytopathies remains to be elucidated. To date, much attention has focused on
immune dysregulation as a causative factor in disruption of normal podocyte function in
MCD. Recently, the anti CD20 immunosuppressive agent rituximab has been shown to
be a safe and effective treatment for steroid-resistant MCD, as well as relapsed refractory
MCD, suggesting that B cell dysregulation may be involved in the pathophysiology of
this disease[28-33]. This last observation indicates that an antibody-mediated process may
play a role in MCD, and potentially other podocytopathies such as LP, where
antibody-mediated injury is a fundamental feature of the systemic disease mechanism.
Recently, practicing pathologists including those within this laboratory have
described a “dust-like” pattern of IgG immunoreactivity on podocyte cell bodies in
kidney biopsies from NS patients that ultimately receive a diagnosis of MCD
(unpublished observations). The presence of IgG immunostaining may indicate the
attachment of antibody on these cells, which immediately suggests the possibility of
antibody targeting of a podocyte antigen. The overall goals of this study are to: (1)
characterize the nature of the IgG immunoreactivity on podocytes in MCD, and (2)
confirm the specificity of the IgG immunoreactivity in MCD by evaluating and
comparing to MCD the staining patterns seen in a panel of disease entities that are also
8known to involve podocyte injury, but are attributable to other known causes. This study
will potentially provide justification for further studies that will look for a potential
podocyte antigen that may be an autoantibody target in MCD.
9Figure 4. Minimal-change disease. A, Glomerulus stained with PAS. Note normal
basement membranes and absence of proliferation. B, Ultrastructural characteristics of
minimal change disease include effacement of foot processes (arrows) and absence
of deposits. CL, capillary lumen; M, mesangium; P, podocyte cell body. White scale bar
= 10 m.
Other Disease Entities Associated with Podocyte Injury
As indicated above, there are several other disease entities that are associated
with podocyte injury, but can be attributed to other causes. These entities can be used to
help demonstrate the specificity of the described podocyte IgG immunoreactivity for
MCD. In this section, we will briefly review the entities used for this purpose in this
study.
Thin Basement Membrane Disease
Thin Basement Membrane Disease (TBMD) is also referred to clinically as
Benign Familial Hematuria. It is a autosomal dominant disorder that has been traced to
mutations in genes encoding α3 or α4 chains of type IV collagen.[17,18] The histology of
TBMD is characterized with diffuse and extremely thin GBMs (compared with 300-400
nm in normal adult individuals). Although mild proteinuria and persistent microscopic
hematuria can be present, renal function is normal and prognosis is excellent. Podocyte
injury is not typically associated with TBMD, and because of this it will provide a
negative control for this study.
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Diabetic Nephropathy
Diabetes mellitus is a major cause of renal morbidity and mortality, and diabetic
nephropathy is one of the leading causes of chronic kidney failure in the United States.
Advanced or end-stage kidney disease occurs in as many as 40% of both
insulin-dependent type 1 diabetics and type 2 diabetics.[19] In diabetic nephropathy,
nonenzymatic glycosylation of GBM and tubular basement membrane occurs, resulting
in structural abnormalities and potentially injury of associated cells, including podocytes.
The afferent and efferent arterioles are also affected by nonenzymatic glycosylation,
resulting in hyaline arteriolosclerosis. Cell injury may also occur through conversion of
glucose into aldose reductase and then into sorbitol, which is osmotically active. The
osmotic activity of sorbitol causes water to enter glomerular capillary endothelial cells
and damage them. The morphologic changes under light microscopy in the glomeruli
include 1) capillary basement membrane thickening, 2) diffuse mesangial sclerosis, and 3)
nodular glomerulosclerosis due to increased type IV collagen in the mesangium. EM
examination typically shows extensive effacement of podocytes. There is often
corresponding heavy proteinuria and NS seen clinically.
Renal Amyloidosis
Amyloidosis is a rare disease characterized by extracellular deposition of fibrils
formed from abnormally polymerized circulating protein. The most common forms of
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systemic amyloidosis with renal involvement are AL-amyloidosis based on plasma cell
dyscrasia, and AA-amyloidosis in chronic inflammatory diseases. Any kidney
compartment may be affected by renal amyloid deposition, including glomerular,
interstitial, tubular or vascular compartments.[20] The Congo red stain, critical for
diagnosis, is specifically used to identify amyloid, and is positive wherever fibrillary
amyloid deposits are present. Patients with glomerular amyloid can present with the
nephrotic syndrome. In early amyloid, the deposits may be sparse but podocyte injury
and proteinuria may be prominent. Eventually, the fibrillary amyloid deposits obliterate
the glomerulus completely, and as a result of destruction of the glomeruli, patients
develop uremia.
Focal Segmental Glomerulosclerosis
Focal segmental glomerulosclerosis (FSGS),is the most common cause of the
nephrotic syndrome (NS) in adults,[2] and the most common primary glomerular disorder
causing end-stage renal disease in the United States, with a prevalence of 4%.[21] The
classic feature of FSGS is progressive glomerular sclerosis. Early in the disease course,
glomerulosclerosis is focal and segmental, affecting only a portion of the glomerulus in a
few glomeruli,. With progression, more widespread and global glomerulosclerosis
develops, leading to renal failure. Focal segmental glomerulosclerosis is frequently
manifest clinically by the nephrotic syndrome with non-selective proteinuria and
hypertension, poor response to glucocoticoids treatment (except 1FSGS-TL). Focal
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segmental glomerulosclerosis is classified into primary (idiopathic) froms and secondary
forms which may be caused by mutation in specific podocyte gene, some specific viruses
infection, some drugs with nephrotoxicity and other adaptive situations.[22] FSGS is also
classified into five histologic variants which recognizes not-otherwise-specified (NOS),
perihilar, cellular, tip, and collapsing disease variants, and is applicable to both primary
and secondary focal segmental glomerulosclerosis.[22] According to the lesions differ
anatomically in their location with respect to the glomerular hilus (vascular pole) and the
tubular pole, and qualitatively with respect to glomerular hypercellularity and capillary
collapse.[23]
Lupus podocytopathy
Lupus podocytopathy is a recently described entity, in which podocyte effacement
and morphologic features suggestive of MCD are found in the setting of pre-existing
systemic lupus erythematosus It is characterized by diffuse podocyte foot process
effacement without peripheral capillary wall immune deposits or glomerular
proliferation.[24] It may represent another specific podocyte insult, in this case potentially
“secondary” to the systemic disease.
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MATERIALS AND METHODS
Renal Biopsies
Kidney biopsies were retrieved from the tissue archives of the Departments of
Pathology and Laboratory Medicine at both Boston Medical Center (BMC) and Brigham
and Women’s Hospital (BWH). We retrieved and examined 16 biopsies from patients
diagnosed with minimal change disease (MCD); 7 biopsies of primary focal segmental
glomerulosclerosis (1FSGS), including 2 of FSGS-TL (“tip lesion”) and 5 of FSGS-NOS
(“not otherwise specified”); 5 biopsies of secondary (adaptive) focal segmental
glomerulosclerosis (2FSGS); 1 biopsy of lupus podocytopathy (LP); 4 biopsies of thin
glomerular basement membrane disease (TBMD); 9 biopsies of diabetic nephropathy
(DN); and 4 biopsies of renal amyloidosis (RA). This study was approved by the human
studies Institutional Review Boards of both institutions.
Quantitative Histopathology Scores
Systematic criteria were used in the conversion of renal biopsy report text
descriptions into numeric scores. These criteria were applied to light and electron
microscopic pathologic features, as well as immunofluorescent staining distribution,
pattern and intensity. A six-point incremental semi-quantitative scale is described as
follows, as used by most renal pathologists, with the text in quotations being equivalent
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to each score: 0=not detectable; trace/T=at limit of detectability, ‘trace;’ 1+=clearly
detectable but weak/‘focal,’ ‘mild;’ 2+=‘moderate;’ 3+=‘strong,’ or ‘extensive;’
4+=maximum intensity/‘diffuse,’ ‘severe.’ In addition, a difference of 2 increments
between samples was determined to be amply sufficient to discriminate between specific
findings. Via chart review, we retrieved antibody immunostaining scores, which were
assessed along glomerular, tubular, vascular and interstitial structures.
Immunofluorescence and Epifluorescence
Most procedures corresponded to the same staining protocol as is used routinely
in our clinical renal pathology laboratory for immunofluorescence studies for diagnostic
purposes. Archived frozen biopsy tissue was retrieved, and fresh frozen sections were cut
at 4 m thickness via cryostat. The general procedure is as follows: Each slide was
labeled with sample number and antiserum target. The labeled frozen sections were air
dried for 10 min, washed in PBS for 10 min, fixed in 95% alcohol for 10 min, and
washed in PBS two times each for 5 min. The slides were wiped dry to remove excess
fluid, and respectively immunostained with FITC-conjugated anti-human IgG antibody
(Dako, F0315), FITC-conjugated anti-human IgG subclass antibodies (The Binding Site,
AF006 to AF009), or FITC-conjugated anti-human kappa and lambda light chains
antibodies (Dako, F0198 and F0199), in routine use for kidney biopsy diagnostic
pathology. The slides were then incubated for 45 min at room temperature, washed in
PBS for 10 min, and mounted using fluorescent mounting medium (Dako, S3023).
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Slides stained to detect complement C4d were stained with primary anti-human C4d
(AbD serotec, 2222-8004), secondary polyclonal rabbit anti-Mouse (Dako, F0313), and
tertiary streptavidin (MP Biomedicals, 623411) antibodies. In addition, some slides were
co-immunostained first with one of two podocyte-specific markers - podocin (SIGMA,
P0372) or synaptopodin (Novus Biological, NBP2-39100), followed by a secondary
anti-IgG antibody (Jackson ImmunoResearch, 711-165-152) which are specific for
podocin and synaptopodin antibodies, then stained with tertiary FITC-conjugated
anti-human IgG antibody (Dako, F0315) and additionally with DAPI (Fisher, D1306).
Slides were examined under an epifluorescence microscope (OLYMPUS) equipped with
a digital computer operated camera (Q Image). Slides previously stained with
FITC-conjugated anti-human Albumin (Dako, F0117), Fibrinogen (Dako, F0111), IgA
(Dako, F0316), IgM (Dako, F0058), C3 (Dako, F201), and C1q (Dako, F0254) for
diagnostic purposes were retrieved from tissue archives for re-examination, or digital
images previously collected from such slides were re-examined.
Immunofluorescence intensity quantification in podocytes
In a subset of cases, digital images of FITC-anti-IgG-immunostained glomeruli
were processed using ImageJ software,[34] to quantify the intensity of podocyte
immunostaining. All podocyte cell body silhouettes in a glomerulus were circled within
their edges (Fig 6 A, C), and the intensity histogram of all pixels within circled regions
was obtained (Fig 6 B, D). The histogram has a large low intensity peak corresponding to
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the background silhouettes of the cells. In control specimens, this peak appears as a
narrow, symmetrical distribution of intensities (Fig 6 B). In specimens with podocyte IgG
staining, a long “tail” of higher intensity pixels appears; this tail corresponds to the IgG
staining (Fig 6 D). The area averaged IgG staining intensity (AAI) is obtained by
integrating the distribution of intensities that are greater than the highest intensity of the
background peak region and dividing by the total circled podocyte area.
Ultrahigh resolution microcopy
Anti-human IgG immunostained sections of kidney biopsies from MCD patients
were examined using the HCBI’s (Harvard Center for Biological Imaging) Zeiss ELYRA
super-resolution microscope.
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RESULTS
Finely granular immunoreactivity for anti-human IgG on podocyte cell bodies is
specific for minimal change disease, and is also observed in some cases of lupus
podocytopathy, tip lesion and NOS variants of primary FSGS
First, we evaluated and compared the pattern of routine diagnostic immunostaining
in a panel of disease entities, including MCD, to confirm the observation of fine granular
IgG immunoreactivity in MCD, and its specificity for this disease. To do this, we
reviewed slides prepared for routine diagnostic immunofluorescence microscopy from
archived renal biopsies from patients with MCD, from other glomerular diseases entities
(1FSGS; 2FSGS, LP, TBMD, DN, and RA), and from non-lesional tissue. When
necessary, we prepared new slides with any of the routine stains that were not available
for direct review. Cases were randomly selected for inclusion from all cases encountered
at two institutions during a four-year period; all cases of MCD and LP encountered
during this period were included in the study. With the exception of TBMD, these disease
entities represent a panel of diagnoses associated with nephrotic range proteinuria, and
the absence of glomerular immune complex deposits (with the exception of LP, which
can exhibit mesangial deposits). For this review, we focused on evidence of
immunoreactivity involving the glomerular visceral epithelial cells, or podocytes. Via
retrospective chart review, we evaluated diagnostic features for each case, to confirm that
biopsy specimens indeed represented our diagnoses of interest.
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As shown in Figure 5, punctate or speckled immunoreactivity with anti-IgG was
observed, of varying intensity and restricted to the podocyte cell bodies, in all biopsies
with a diagnosis of MCD, lupus podocytopathy, and some cases of the tip lesion and
NOS variant of 1FSGS (Figure 5 A-C), and was not observed in other cortical structures
in those biopsies. Interestingly, two cases of TBMD showed trace punctate
immunoreactivity for IgG on podocytes. In all cases with punctate podocyte IgG staining,
with the exception of the TBMD cases, we also observed at least weak corresponding
punctate immunoreactivity for kappa light chain, lambda light chain, or both (Table 1).
One MCD case, representing recurrence in a transplanted kidney, also exhibited punctate
podocyte immunoreactivity for C4d. Otherwise, we did not observe corresponding
immunoreactivity on podocytes with any of the other routine stains in these cases. With
few exceptions, the punctate immunoreactivity was almost always diffuse and global (see
Table 2). In all cases of 2FSGS, TBMD, RA and DN, as well as normal kidney tissue, a
punctate or speckled pattern of immunoreactivity for IgG or any other immunoreactants
was not observed on podocytes or elsewhere in the tissue (Figure 5 D-H; Table 1). In
some cases with or without speckled podocyte immunoreactivity for IgG, segmental
coarse granular immunoreactivity for albumin and various combinations of other
immunoreactants including IgG, was observed in podocyte cell bodies in some glomeruli,
typical of epithelial protein reabsorption (Figure 5 I), and distinct from the speckled
reactivity when present. Summarized in Table 2 is the number of cases among each
diagnostic group exhibiting punctate immunoreactivity for anti-human IgG, IgA, IgM,
kappa light chain, lambda light chain, C3, C1q, and C4d on podocyte cell bodies.
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Preliminary studies were performed to develop a method of quantification of the
observed punctate immunoreactivity, using image processing techniques. These studies
performed on four glomeruli indicated that repeated independent measurements fall
within 5% of the mean. Example results for two glomeruli (1 TBMD, 1 MCD) are shown
in Figure 6. Although the results were promising, the technique was not utilized further as
it was seen that there was essentially no podocyte immunoreactivity detected in disease
entities other than the podocytopathies; thus quantitative comparisons were determined to
be unnecessary.
A putative antigen in the primary podocytopathies is targeted by intact oligoclonal
immunoglobulin, and is associated with podocyte cell bodies.
Of the biopsies reviewed above, all available ‘primary podocytopathy’ and lupus
podocytopathy specimens were immunostained with FITC-conjugated antibodies against
human C4d and IgG subclasses, including IgG1, IgG2, IgG3, and IgG4. We graded and
characterized the speckled podocyte immunoreactivity for the IgG subclasses, as well as
kappa and lambda light chains, as described previously (Table 2). We observed a wide
variety of combinations and varying intensities of IgG subtype and light chain
immunoreactivity, as shown in Table 2. Epifluorescence photomicrographs of glomeruli
of four representative cases of MCD, immunostained with this panel of antibodies, are
shown in Figure 7.
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Figure 5. Epifluorescence micrographs of human kidney biopsies immunostained
with FITC-conjugated anti-IgG antibody, showing presence or absence of fine
granular staining over podocyte cell bodies. Arrows in insets (from region highlighted
by yellow box) indicate silhouettes of podocyte cell bodies, and terms in parentheses
refer to the strength of the finely granular IgG staining morphology, from 0 (no staining)
to 4+ (strongest immunoreactivity). 5 A-C: Podocyte cell bodies show punctate or
speckled staining with anti-IgG in image from biopsies with a diagnosis of MCD (2+), 1
FSGS-TL (1+) and LP (1+). 5 D-H: Renal biopsies from other disease entities show no
punctate immunoreactivity of IgG over podocyte cell bodies. 5 I: Example of epithelial
protein reabsorption in a case of MCD, evident as segmental irregular and coarse granular
immunoreactivity for IgG observed in podocyte cell bodies, and distinct from the finely
granular immunoreactivity seen diffusely. In all biopsies, glomerular basement
membranes show dull linear staining. Scale bar = 10 m. MCD: minimal change disease;
1FSGS: primary (idiopathic) focal segmental glomerulosclerosis; 1FSGS-TL: tip lesion
variant of 1FSGS; LP: lupus podocytopathy; 2FSGS: secondary (adaptive) focal
segmental glomerulosclerosis; TBMD: thin basement membrane disease; DN: diabetic
nephropathy; RA: renal amyloidosis; Normal: normal kidney.
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Disease
Albumin(n) Fibrinogen(n) IgG(n) IgA(n)
P N P N P N P N
MCD(n=16) 0 16 0 16
16
(1,2,6,6,1)
0 0 16
1FSGS(n=7) 0 7 0 7
2
(0,0,1,1,0)
5 0 7
LP(n=1) 0 1 0 1
1
(0,0,1,0,0)
0 0 1
2FSGS(n=5) 0 5 0 5 0 5 0 5
TBMD(n=4) 0 4 0 4
2
(2,0,0,0,0)
2 0 4
DN(n=9) 0 9 0 9 0 9 0 9
RA(n=4) 0 4 0 4 0 4 0 4
Normal(n=1) 0 1 0 1 0 1 0 1
Disease
IgM(n) C3(n) C1q(n) kappa(n) lambda(n)
P N P N P N P N P N
MCD(n=16) 0 16 0 16 0 16
13
(5,1,5,2,0)
3
13
(6,2,4,1,0)
3
1FSGS(n=7) 0 7 0 7 0 7
1
(0,0,1,0,0)
6
2
(0,1,0,1,0)
5
LP(n=1) 0 1 0 1 0 1
1
(0,1,0,0,0)
0
1
(1,0,0,0,0)
0
2FSGS(n=5) 0 5 0 5 0 5 0 5 0 5
TBMD(n=4) 0 4 0 4 0 4
1
(1,0,0,0,0)
3
1
(1,0,0,0,0)
3
DN(n=9) 0 9 0 9 0 9 0 9 0 9
RA(n=4) 0 4 0 4 0 4 0 4 0 4
Normal(n=1) 0 1 0 1 0 1 0 1 0 1
Table 1. Summarized percentages of positive staining, specifically in the form of
punctate or speckled staining on podocyte cell bodies, for FITC-conjugated
anti-Albumin, -Fibrinogen, -IgG, -IgA, -IgM, -C3, -C1q, -kappa light chain,
and –lambda light chain antibodies, in archived human kidney biopsy tissue. n=total
number of cases in each disease category. P: number of cases with positive fine granular
immunoreactivity identified on podocyte cell bodies. For IgG, kappa, and lambda,
breakdown of number of cases with specific grade of intensity on 0 (no involvement) to
4+ (severe involvement) scale, is also shown parenthetically as (trace,1+,2+,3+,4+). N:
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Number of cases with no immunoreactivity identified on podocyte cell bodies. MCD:
minimal change disease; 1FSGS: primary (idiopathic) focal segmental glomerulosclerosis;
2FSGS: secondary (adaptive) focal segmental glomerulosclerosis; LP: lupus
podocytopathy; TBMD: thin basement membrane disease; DN: diabetic nephropathy; RA:
renal amyloidosis; Normal: normal kidney tissue.
Figure 6. Immunofluorescence intensity quantification in podocytes
immunostainined for IgG. A,C: Images of FITC-anti-IgG-immunostained glomeruli,
from a case of TBMD (A), and a case of MCD (C). Brighter fine punctate
immunoreactivity is noted over podocytes in the MCD case, but not in the TBMD case.
Podocyte cell bodies have been segmented (“circled”) for intensity quantification;
segmented areas are indicated by thin gray lines. B, D: Histograms of intensity intensity
of all pixels within segmented regions corresponding to images in A and C. The intensity
histogram from the TBMD image shows a simple, narrow peak at low intensity,
representing background intensity. The intensity histogram of the MCD image shows a
similar low intensity peak, but also shows a higher intensity, wide “tail” region that
represents the MCD-associated speckled immunoreactivity. The area averaged IgG
staining intensity (AAI) was obtained by integrating the distribution of intensities that are
greater than the highest intensity of background peak region and dividing by the total
circled podocyte area. The resulting AAI for the MCD case is markedly higher than that
of the TBMD case.
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ID No. IgG IgG1 IgG2 IgG3 IgG4 kappa lambda C4d
MCD-1 3+ 2+ - 3+ 0 T,D 0 T,D 0 0
MCD-2 3+ 2+ 0 0 1+,D 0 3+ 0
MCD-3 T T,S 0 T 0 0 T,S 0
MCD-4 2+ T,DS 0 2+,S 2+ 1+,D T 0
MCD-5 3+ 2+,D 0 0 1+,D 2+ T,D 0
MCD-6 2+ T 0 1+ 2+ T 2+ 0
MCD-7 2+ * * * * 2+,S
1+ -
2+,S
0
MCD-8 1+ T 0 T - 1+ 1+ T - 1+ T 0
MCD-9(Tx) 4+ 3+ 0 2+ - 3+ 0 3+ - 4+ 2+ 3+
MCD-10 T 0 0 0 T 0 T 0
MCD-11 2+ 2+ 0 T 1+ 2+ T 0
MCD-12 3+ 1+ 0 2+ - 3+ 2+ 2+ 1+ 0
MCD-13 1+ T 0 0 0 T 0 0
MCD-14 2+ T - 1+ 0 0 2+ T 1+ - 2+ 0
MCD-15 3+ T 0 0 2+ - 3+ 2+ - 3+ 0 0
MCD-16
(GVHD)
2+ 1+ 2+ 0 0 2+ 2+ 0
FSGS-1 0 0 0 0 0 0 0 0
FSGS-2 0 0 0 0 0 0 0 0
FSGS-3(TL) 0 0 0 0 0 0 0 0
FSGS-4 0 0 0 0 0 0 0 0
FSGS-5(TL) 2+ 2+ 0 0 0 2+ 1+ - 2+ 0
FSGS-6 0 0 0 0 0 0 0 0
FSGS-7(NOS) 3+ 3+ 1+ 2+ T 0 3+ T
LP-1 2+ 2+ 0 0 0 1+ T T
Table 2. Quantification of IgG, IgG subclass, kappa and lambda light chain and
C4d staining across renal biopsy disease states with positive findings. MCD: minimal
change disease; 1FSGS: primary (idiopathic) focal segmental glomerulosclerosis; LP:
lupus podocytopathy; Tx, transplant biopsy; GVHD, graft versus host disease. Intensity
of dusting on podocyte cell bodies graded on 0 (no involvement) to 4+ (severe
involvement) scale. Codes for immunofluorescence findings: T, trace; D, dull; S,
segmental; *, no data.
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Figure 7. Representative epifluorescence micrographs of human kidney biopsy from
4 patients with minimal change disease, immunostained with subclass specific
FITC-conjugated anti-IgG, and FITC-conjugated anti-kappa and anti-lambda light
chain antibodies. Podocyte cell bodies show punctate or speckled staining for specific
heavy and light chain subclasses (IgG1, IgG4, IgG3, lambda and kappa light chain),
whereas IgG2 appears negative in all cases. Glomerular basement membranes show dull
linear staining in all images. Staining intensity (indicated parenthetically in each figure)
is scored on a 0 to 4+ scale. T: Trace. Scale bar = 10 m
Finely granular immunoreactivity of anti-human IgG in primary podocytopathy
cases is not associated with the podocyte-specific protein synaptopodin.
We co-immunostained several ‘primary podocytopathy’ (MCD, and tip lesion
variant of 1FSGS, and LP) cases with FITC-conjugated anti-human IgG and
anti-synaptopodin antibodies, along with DAPI staining to highlight cell nuclei. Sections
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were examined under an epifluorescence microscope and then these three stains were
merged into a single image (Figure 8). As shown representatively in Figure 8, fine
granular immunoreactivity of anti-IgG and synaptopodin do not appear to be strongly
co-localized over podocyte cell bodies in biopsies with a diagnosis of MCD. The same
phenomenon was observed in normal kidney tissue.
Diffuse effacement of foot processes in the primary podocytopathies is associated
with finely linear staining of anti-IgG over filtration slit diaphragms, and may
indicate potential targeting of filtration slit-associated antigens.
We co-immunostained all ‘primary podocytopathy’ specimens (MCD, LP and
1FSGS) specimens and other control disease entities (normal kidney, TBMD, DN and
2FSGS) with FITC-conjugated anti-human IgG, anti-podocin, and DAPI staining
(highlighting cell nuclei). Sections were examined under an epifluorescence microscope
and these stains were merged into a single image (Figure 9). As shown representatively in
Figure 9, finely diffuse linear staining of anti-IgG was observed on capillary loops of
biopsies with a diagnosis of MCD, 1FSGS, and LP (Figure 9). More homogeneous and
less distinct anti-IgG filtration slit diaphragm staining was observed on capillary loops of
biopsies with a diagnosis of TBMD, DN and 2FSGS, and normal kidney tissue (Figure
9).
We examined FITC-conjugated anti-human IgG immunostained MCD specimens
using ultra high-resolution microscopy. Much more clearly visible granular and
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curvilinear patterns of anti-IgG immunoreactivity can be seen, which are highly
suggestive of residual filtration slits surrounding effaced foot processes (Figure 10). This
suggests that IgG may be targeting a filtration slit-associated antigen, such as podocin.
Figure 8. Epifluorescence micrographs of human kidney biopsies co-immunostained
with FITC-conjugated anti-IgG (green), Synaptopodin (red), and DAPI (blue). In
biopsy with diagnosis of MCD, podocyte cell bodies show punctate or speckled
immunostaining with anti-IgG but not synaptopodin. Thus the MCD biopsies did not
show co-localization of fine granular IgG staining and synaptopodin staining in merged
images. Synaptopodin staining does highlight podocyte processes in both MCD and
Normal examples. Each photomicrograph represents a field approximately 50 nm wide.
MCD: minimal change disease; Normal: normal kidney.
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Figure 9. Epifluorescence micrographs of human kidney biopsies co-immunostained
with FITC-conjugated anti-IgG (green), Podocin (red), and DAPI (blue). Filtration
slit diaphragms show diffuse linear immunostaining with anti-IgG and podocin in images
from biopsies with diagnoses of MCD, LP, and 1FSGS. The other disease entities
(2FSGS, TBMD, DN) and normal kidney show more homogeneous appearance of
podocin staining and filtration slit diaphragms are much less distinct (orange color of
filtration slits in merged images). Each photomicrograph represents a field approximately
50 mm wide. MCD: minimal change disease; LP: lupus podocytopathy; 1FSGS: primary
(idiopathic) focal segmental glomerulosclerosis; 2FSGS: secondary (adaptive) focal
segmental glomerulosclerosis; TBMD: thin basement membrane disease; DN: diabetic
nephropathy; Normal: normal kidney.
Figure 10. Ultra-high resolution anti-IgG immunostained epifluorescence images of
glomeruli from MCD biopsy. A) Conventional epifluorescence microscopy. Fine
granular staining for IgG in MCD, adjacent to GBM, as seen under conventional
immunofluorescence microscopy (Figure 10A, arrows). The glomerular basement
membrane (GBM) is the diffusely, mildly immunoreactive ribbon-like structure. B, C)
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Ultra-high resolution epifluorescence microscopy. Enhanced anti-IgG immunostaining
using a Zeiss ELYRA super resolution microscope reveals curvilinear patterns of staining
just outside of the GBM, highly suggestive of residual filtration slits surrounding effaced
foot processes, 100x objective (Figure 10B). Higher magnification further defines the
curvilinear staining pattern of anti-IgG antibodies (Figure 11C, arrows). Bars are 5 mm in
A and B; 3 mm in C.
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DISCUSSION
In the present study, we describe for the first time that, in human biopsies, the
presence of oligoclonal finely granular staining for anti-IgG on podocyte cell bodies, is
specifically associated with the presence of a ‘primary podocytopathy’, including
essentially all biopsies diagnosed as MCD, and some cases of tip lesion variants of
1FSGS. We also observed this finding in a case best categorized using the new moniker
‘lupus podocytopathy’, which refers to cases of lupus nephritis without peripheral
capillary wall immune deposits in the glomeruli, but that do show severe podocyte injury.
We did not observe any similar fine granular immunostaining on podocytes in other renal
disease states, including several associated with severe podocyte injury. In addition,
although we found the fine granular immunoreactivity of anti-IgG is not highly
co-localized with the podocyte-specific marker synaptopodin, we did observe using
super-resolution microscopy that in these cases there is immunoreactivity for IgG along
filtration slits, that is potentially co-localized with the filtration slit-diaphragm-associated
antigen podocin (Figures. 8, 9, 10).
This study suggests a heretofore undescribed mechanistic pathway for MCD and
related podocytopathies, involving antibody-mediated immunity, that is associated with
antibody binding specifically to the podocyte. The potential etiology of the ‘finely
granular dusting’ of IgG identified over podocyte cell bodies in this case series may
involve B cell dysregulation, or T cell dysregulation leading to abnormal B cell activation
and/or production of circulating cytokines. Several lines of evidence support this line of
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reasoning, particularly with regards to MCD. Levels of CD23, a soluble marker of B cell
activation, have been shown to be elevated during episodes of MCD relapse[35]. CD80
(B7-1), a costimulatory molecule known to be expressed on antigen presenting cells as
well as podocytes, has been shown by Garin and colleagues to exhibit increased
expression on podocytes during relapsed MCD, but not during disease remission[37]. This
increase in CD80 expression was suggested to be a mechanism for the proteinuria seen in
MCD[37]. Additionally, CTLA-4, a transmembrane protein involved in regulation of T
cell populations, appears to regulate CD80 expression in podocytes, and to be altered
in minimal change disease patients[36,38]. CD80 is inhibited by binding to CTLA-4, which
is a product expressed on regulatory T cells[38]. Factors known to induce CD80
expression on podocytes include IL-13 and microbial antigens, via processing by
Toll-like receptors[38]. However, additional work is needed to clarify these observations,
and determine if our finding of IgG immunoreactivity on podocytes is associated with
these putative mechanisms.
In support of the proposed antigen-antibody interaction mechanism in MCD,
several biopsies displaying podocyte fine dusting in this case series are associated with
autoimmunity, including one case of lupus podocytopathy (LP). LP is a recently
described pathologic entity defined by the presence of foot process effacement visible
under EM, concurrent with morphologic evidence of lupus nephritis[24]. This entity has
also been previously reported to display glomerular mesangial IgG deposition, consistent
with our findings in this study[24]. It is reasonable, therefore, to consider the role that
autoimmunity may play in the etiology of this group of diseases. Our findings suggest
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that a putative antigen in the primary podocytopathies is targeted by intact oligoclonal
immunoglobulin, and is associated with podocyte cell bodies. Recent studies have
demonstrated that M-type phospholipase A2 receptor (PLA2R) and thrombospondin
type-1 domain-containing 7A (THSD7A) were expressed in podocyte in human
glomeruli, and co-localized with circulating IgG4 autoantibodies in glomerular immune
deposits of patients with membranous nephropathy, using immunoblotting and mass
spectrometry of both human serum and isolated renal glomeruli[39, 40]. Our results suggest
the possibility of a similar sort of antigen-antibody interaction, albeit in the absence of
outright immune complex deposition, as is seen in membranous nephropathy. It is unclear
how such interaction might occur without immune complex deposition. One possibility is
that, if the antigen is present at the apical podocyte surface, as opposed to the basal
surface as in the case of the antigens associated with membranous nephropathy, then
perhaps the mechanobiologic environment, with perhaps more dynamic fluid flow, may
disallow the accumulation of immune complexes. This in turn suggests the possibility
that early, small immune complexes that have been washed away, may be detectable in
the urine, and may serve as a marker for this particular disease mechanism.
In addition to a possible urine marker, our studies could point to other new,
simpler, more rapidly-available, more reliable and/or more specific diagnostic approaches
for MCD. Up to now, the diagnosis of MCD has been strictly dependent upon the
presence of characteristic morphological changes, particularly ultrastructure of the
podocyte as seen by electron microscope, thus the diagnosis of MCD is usually not
mechanism-based, and therefore could be uncertain. Our work suggests the possibility of
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diagnostic features that may be directly associated with disease mechanism.
Furthermore, MCD is not the only disease which is associated with severe podocyte
injury and foot process effacement under electron microscope. The morphological
features are also present in other proteinuric states, including idiopathic focal segmental
glomerulosclerosis (FSGS), familial forms of FSGS, adaptive FSGS, membranous
glomerulopathy, renal amyloidosis and diabetic nephropathy, all of which often exhibit
extensive or diffuse foot process effacement and podocyte injury, and may exhibit
variable expression of other features that are specific for these diagnoses (e.g., amyloid or
membranous deposits, diabetic changes in glomeruli, segmental sclerosis, etc). Our
studies suggest that many of these other disease entities can be ruled out by the absence
of fine granular immunoreactivity of anti-IgG on podocyte. This is important, as the
treatment approaches for these diseases often deviate from that used for MCD, and a
highly specific diagnostic approach for MCD would therefore improve treatment
decisions. In particular, a new diagnostic maker of MCD could reduce or eliminate
steroid exposure when it is not needed and provide the opportunity for the earliest
initiation of a tailored treatment approach.
Another issue with MCD diagnosis is that the ultrastructural examination requires
at least a two or three-day turn-around time, and significant technical and material
resources. As a result, patients are usually treated presumptively with steroids while a
diagnosis is awaited. Our findings could lead to an improved diagnostic approach that is
IF dependent, which would require only one day turn-around time, and less labor and
material resources.
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To definitively prove an antibody-antigen interaction in MCD, and its causality of
podocyte injury, additional studies are needed. One approach would involve
identification of specific podocyte structures in biopsies from primary podocytopathy
cases that are antibody targets, using immunogold electron microscopy. This could be
accomplished using gold-conjugated anti-FITC as secondary antibody, and
FITC-anti-IgG (used clinically) as primary antibody, to identify precisely where IgG is
bound to podocyte structures. Staining for IgG in addition to podocyte markers, or with
other components of deposited material such as complement (so-called ‘double staining’)
may also be used to assist in identifying precise protein-protein interactions. Anti-kappa
and anti-lambda staining, with immunogold, may also be helpful to confirm antibody
localization, since in many cases we observed light chain monoclonality in the fine
granular podocyte immunoreactivity.
In order to identify the target of an antigen-antibody interaction, an approach can
be taken similar to that described for identifying antigens in membranous nephropathy[25,
26]. This approach would involve reaction of serum and/or urine samples from affected
individuals, presumed to contain anti-podocyte antibodies, to human glomerular extracts,
via immunoblotting. Any reactive band would then be studied using mass spectrometry to
identify the target antigen of podocyte IgG staining. If antibodies against the target
molecule are available, they can be used to confirm the presence and nature of the target
podocyte antigen. Ultimately, these studies may help to reveal new mechanisms of direct
podocyte injury in the primary podocytopathies, and contribute to our understanding of
podocyte pathophysiology.
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CONCLUSION
Our observation of finely granular immunoreactivity of anti-IgG over podocyte
cell bodies appears to have the potential to serve as a new, simpler, rapid, more specific
and reliable diagnostic marker for these disease entities, that could reduce or eliminate
steroid exposure when it is not needed, and provide the opportunity for earlier initiation
of a tailored treatment approach. This also suggests the possibility of a direct
antibody-mediated mechanism of podocyte injury in the primary podocytopathies, and
potentially provides new targets for treatment of this group of diseases.
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